Melanotic Neuroectodermal Tumor of Infancy

Back

Background

Melanotic neuroectodermal tumor of infancy (MNTI) is a relatively uncommon osteolytic-pigmented neoplasm that primarily affects the jaws of newborn infants.[1] The lesion has had an interesting history since its initial description by Krompecher in 1918 as a congenital melanocarcinoma.[2]

For the next 5 decades, the lesion was reported under a variety of different names as succeeding authors attempted to identify the cell of origin. Some of the terms applied to this lesion included pigmented ameloblastoma, retinal anlage tumor, melanotic progonoma, melanotic adamantinoma, and pigmented epulis of infancy.[3, 4, 5] These terms reflected theories of suspected origin from the odontogenic apparatus, the pigmented anlage of the retina, or the sensory neuroectodermal tissues.

In 1966, Borello and Gorlin reported a case with high urinary excretion of vanillylmandelic acid (VMA), suggesting a neural crest origin, and they proposed the term melanotic neuroectodermal tumor of infancy.[6] Since then, numerous histochemical, immunohistochemical, electron microscopic, and tissue culture studies have supported the neural crest origin and confirmed the preferred term of melanotic neuroectodermal tumor of infancy.[7, 8, 9, 10]

Pathophysiology

Several patients with melanotic neuroectodermal tumor of infancy (MNTI) have demonstrated a high urinary excretion of VMA.[6, 11] This finding adds credence to a neural crest origin because elevated VMA has been reported in neuroblastoma, ganglioneuroblastoma, pheochromocytoma,[12] and other neural crest tumors. However, the presence of elevated urinary VMA is not diagnostic for MNTI.

Epidemiology

Frequency

Melanotic neuroectodermal tumor of infancy (MNTI) is a rare neoplasm and approximately 485 cases have been reported in the literature to date worldwide.

Sex

Melanotic neuroectodermal tumor of infancy (MNTI) has a slight male predilection, with a male-to-female ratio of 1.3:1.[13]

Age

Most patients, by some estimates more than 90%, present with the tumor in the first year of life, usually from age 1-6 months, with a peak between the second and sixth month of life.[14] A few cases of melanotic neuroectodermal tumor of infancy (MNTI) have been reported in adults, notably, a 23-year-old man, a 39-year-old woman, and a 67-year-old woman.[15, 16, 17] However, only 9% of cases are seen in patients older than 12 months.[18]

Prognosis

Most melanotic neuroectodermal tumors of infancy (MNTIs) are benign and effectively managed by aggressive surgical excision. Reconstruction may be challenging. In a systematic review, a recurrence rate of 20% was found, with the highest relative risk for recidivation being found in the mandible and skull (33.3% and 31.8%, respectively). Most recurrences appear to occur within 4 weeks after the operation. A comprehensive systematic review of 472 cases of MNTI found that age at diagnosis is an important prognostic indicator in these tumors. Infants diagnosed within the first 2 months of birth have a shorter disease-free survival period and the recurrence tends to occur within only 6 months from treatment, while patients older then 4.5 months have minimal risk of recurrence.[13] Unfortunately, reports have shown that recurrent tumors tend to behave more aggressively and involve other anatomic structures such as the orbit and skull base.[19, 20] Additionally, a malignancy rate of 6.5% has been reported for these tumors, with most malignant cases occurring in the skull and brain. Only very few tumors produce metastases and death.[18]

History

Although melanotic neuroectodermal tumor of infancy (MNTI) is classified as a benign lesion, it is often clinically worrisome because of its rapid onset and alarming local growth rate.[19, 21] Often, sucking and feeding are impaired secondary to the swelling.[11, 22] The patient usually is asymptomatic.

Physical Examination

More than 90% of cases of melanotic neuroectodermal tumor of infancy (MNTI) occur in the head and neck region, with a striking predilection for the anterior portion of the maxilla. In fact, the maxillary bone is the location of approximately 61% of reported cases.[18] Other less frequently affected sites include the skull (16%), the epididymis and testis (9%), the mandible (6%), and the brain (6%).[18] A few cases have been reported in unusual locations such as the subcutaneous soft tissue of the thigh and forearm, the femur, the fibula, the mediastinum, the shoulder, and the uterus.[7, 23, 24, 25, 26]

All but two of the reported cases in the literature have been solitary lesions.[27, 28]

The typical MNTI begins as a nonulcerated, lightly pigmented, blue or black lesion on the anterior aspect of the maxilla and rapidly expands to form a swelling or tumescence (see the image below) that is cosmetically obvious to the parents of the infant.



View Image

Melanotic neuroectodermal tumor of infancy presents as a rapidly growing bluish mass on the anterior aspect of the maxilla.

The intraoral lesion appears as a sessile, lobulated mass, often reaching 2-4 cm in diameter by the time of diagnosis. Bone destruction and displacement of teeth often occur because of the intraosseous location in the maxilla. No thrill or pulse can be elicited from the MNTI. Although the lesion expands rapidly, the overlying mucosa usually remains intact.

Laboratory Studies

Typically, the hematologic laboratory values and the blood chemistry values are within the reference range. The only noteworthy laboratory value documented in some but not all patients with melanotic neuroectodermal tumor of infancy (MNTI) is an increase in the urinary level of vanillylmandelic acid (VMA).[6] Elevated VMA has been reported in other tumors of neural crest origin, such as pheochromocytoma, ganglioneuroblastoma, retinoblastoma, and neuroblastoma. The urinary level of VMA may return to the reference range after surgical removal of an MNTI that has caused elevated VMA.[1] Additionally, no correlation between the presence of elevated VMA and more aggressive or malignant clinical behavior has been shown.

Imaging Studies

Plain dental radiography, CT scanning, and MRI have been used to evaluate the content and the extent of melanotic neuroectodermal tumor of infancy (MNTI).

Conventional radiographs of MNTI within bone usually show a well-circumscribed or a diffuse, ill-defined radiolucency with bony expansion.[18] The bone is destroyed as the tumor advances, suggesting a malignant process. Although a few cases have been described as multiloculated, most MNTIs are unilocular. In its typical premaxillary position, the tumor can displace the developing deciduous and permanent dentition. Occasionally, an osteogenic reaction in the form of a faint spiculated or “sunburst” appearance may be seen that can be mistaken for an osteosarcoma.[1] These characteristics are noted best on maxillary occlusal, sinus, or periapical images of the involved area.

CT scanning defines the extent of the lesion, clearly delineates osseous involvement, and provides a good basis for surgical planning. Maxillary lesions usually demonstrate the radiolucent bony lesion causing bony expansion, sometimes with “free-floating teeth”.[29] Calvarial lesions may show spiculation and hyperostosis and the adjacent bones can be thickened as a result of reactive sclerosis.[30]

See the image below.



View Image

Axial CT, bone window, noncontrasted scan demonstrates expansile lytic lesion of the left maxilla producing displacement of dental follicles.

Additionally, MRI with gadolinium contrast can be used to evaluate the bony extent of the lesion. Most maxillary and calvarial MNTIs appear isointense or hypointense on T1-weighted images and hypointense on T-2 weighted images[29, 30] ; however, for the few MNTIs that contain a large amount of melanin, a higher signal intensity often occurs.[31, 32, 33] MNTIs may contain areas of reduced signal on both T1- and T2-weighted images, corresponding to areas of calcification, or in tumor lying near hyperostotic bone.[30] At no time are flow voids suggestive of a central hemangioma.

Procedures

Upon completion of the clinical examination of the patient and the imaging studies and urinalysis, the definitive diagnosis of melanotic neuroectodermal tumor of infancy (MNTI) is based on the histologic evaluation of a surgical specimen.

Histologic Findings

Grossly, the specimen has a gray, hard, rubbery consistency with foci of blue-black pigmentation.[34] Additionally, entrapped developing tooth buds may be noted in the specimen as the melanotic neuroectodermal tumor of infancy (MNTI) grows in and around the odontogenic apparatus.

The tumor cells form nests, tubules, or alveolarlike structures within a dense, collagenous, fibrous stroma.[1] The peripheral borders are faintly noted, at best, by a thin, delicate, fibrous layer; however, most often, this nonencapsulated tumor shows local infiltration into the adjacent bone.

The histologic appearance of an MNTI is unique and characteristic in that a distinct biphasic pattern exists, as shown in the image below. The first cell population consists of large, polygonal, epithelioid cells, which appear as islands or as forming tubular or alveolarlike structures. These large cells appear, under hematoxylin and eosin staining, to have pale abundant cytoplasm and pale nuclei with finely dispersed chromatin. These cells often contain the melanin pigment that gives the MNTI its blue-black clinical appearance.[1, 35] Fontana stain can be used to enhance the demonstration of the melanin pigment.



View Image

The biphasic population of cells demonstrates alveolar structures lined by cuboidal epithelioid cells demonstrating granules of dark-brown melanin pig....

The larger polygonal cells are at the periphery of the alveolar spaces, while the central portion contains the second smaller characteristic cell type. These cells are lymphocyte-like or neuroblastlike with small, dark nuclei and little, if any, cytoplasm. These cells occasionally also form isolated loose clusters of their own within the fibrous stroma.[1] Throughout the lesion, mitoses are rare but, when present, are normal in appearance. Cellular pleomorphism is scant. The few reported malignant cases of MNTI have little variation from the description above other than an increase in mitoses (3 or more per high-power field), hypercellularity, and focal necrosis.[36] The malignant diagnosis is more one of increased growth rate, infiltration, and metastases. Metastatic lesions have been described in lymph nodes, the liver, the pleura, bone marrow, soft tissues, and the pelvis.[9, 37, 38]

Immunohistochemistry is helpful in cases that are more difficult to diagnose. The larger polygonal cells express cytokeratins 8 and 18, protein gene product (PGP) 9.5, neuron-specific enolase, and melanoma-associated antigen ([human melanoma black [HMB]–45) and they are usually negative for S-100. The small, neuroblastlike cells express CD56, neuron-specific enolase and, in a few cases, PGP 9.5 and synaptophysin.[34, 39, 40] An uncommon CD99 expression in the large epithelioid cells has been reported in two clinically aggressive tumors.[24, 39] However, the prognostic significance of CD99 expression in MNTIs has yet to be further investigated.

A study analyzing cell-cycle regulatory proteins in MNTI found that MDM-2 protein, the product of a proto-oncogene that inhibits the regulatory function of the p53 protein, was expressed by the larger cells. The same researchers have also found greater expression of cyclin D1 and other cell-cycle regulatory proteins, such as cyclin A and proliferating cell nuclear antigen in the larger cells, suggesting that these cells are the more proliferative element of the tumor.[41]

Electron microscopic examination demonstrates ultrastructural evidence of neural, epithelial, and melanocytic features. Fine, delicate cytoplasmic fibers are suggestive of neurofibrils, reminiscent of glial tissue. Typically, some of the cells demonstrate neurosecretory granules. Evidence exists of basal laminae and interdigitating desmosomal attachments to adjacent cells, which is suggestive of epithelial features in some cells. Finally, melanosomes are noted in many of the cuboidal cells.[7, 8, 10, 40]

The polygonal cells noted for their melanin production have been cultured in vitro. These cells developed long dendritic processes suggestive of their neural crest origin. Additionally, expression of melanotransferrin messenger RNA transcripts within the tumor was observed using a reverse transcriptase-polymerase reaction method, further confirming the neural crest origin of the tumor cells.[9, 42] The other small, dark, neuroblastlike cells have also been studied and although one case of MNTI has been reported to show chromosomal abnormalities analogous to neuroblastoma,[19] another earlier molecular genetic study found no genetic basis to link MNTI to neuroblastoma.[43] Accordingly, further molecular studies appear warranted in order to better elucidate the relationship between these two tumors.

Surgical Care

The treatment of choice for melanotic neuroectodermal tumor of infancy (MNTI) is surgical excision, and it is usually curative.[11, 18, 44]  Existing teeth and developing teeth must be sacrificed when they lie within the lesion or near the borders of an MNTI. Some controversy still exists regarding the amount of adjacent bone that needs to be removed during the surgical procedure. Many clinicians advocate for a 5-mm margin of healthy tissue be included with the surgical specimen.[45, 46] Others advocate for only enucleation of the tumor followed by curettage of the bony cavity.[11, 47]

Adjuvant and Neoadjuvant Therapies

Complete tumor removal of the melanotic neuroectodermal tumor of infancy (MNTI) may not be the goal when it may sacrifice vital structures such as the orbital or intracranial contents. In such cases, adjuvant chemotherapy may be beneficial.[48] Cases of primarily inoperable MNTIs have also been reported, for which chemotherapy was performed to reduce extension of the tumor mass before surgical treatment.[49, 50] Only rarely has radiotherapy been successfully used in combination with surgical treatment or in combination with chemotherapy and surgical treatment for MNTI.[51, 52]

Local recurrence is a possibility and has been documented to range from 10-60% of patients, depending on the study. Overall, recurrence has been reported to occur in 20% of cases.[18] The recurrent lesions, possibly secondary to inadequate excision or multicentricity, usually become apparent within the first year after surgery. In instances of inoperable recurrence or when clear margins are impossible to obtain, chemotherapy and/or radiation therapy have been used.[20, 51, 52, 53]

Neven et al in 2008 advocate for adjuvant chemotherapy in cases of multiple aggressive recurrences and/or inoperable tumors.[19] These authors followed a successful neuroblastoma chemotherapy protocol for a recurring aggressive MNTI, which, in molecular studies, showed 1p deletion and gain of chromosome 7q, analogous to a neuroblastoma. Hence, in cases in which chemotherapy is necessary, it appears that molecular studies of the resection specimen might be beneficial to identify which protocol will have the most successful results.

Interestingly, Davis et al in 2015 reported a unique mixed response of an aggressive recurrent tumor to neoadjuvant chemotherapy using agents known to be effective for neuroblastomalike tumors (vincristine and cyclophosphamide).[20] The postchemotherapy surgical specimen showed that the treatment resulted in complete obliteration of the neuroblastlike cells, but only a minimal effect in reducing the larger, polygonal cell population.

Gomes et al in 2015 found a BRAFV600E oncogenic mutation in one case of MNTI of the three studied. This might suggest that currently available BRAF-targeted therapies might be successful alternative treatments for aggressive MNTIs harboring the mutation.[54]

A 2016 study performed exhaustive genomic, transcriptomic, epigenetic, and pathological characterization of a MNTI involving the fibula of a 2-month-old baby girl. Whole-exome analysis of genomic DNA from both the tumor and blood indicated a heterozygous, unique-germline, loss-of-function mutation in CDKN2A (p16INK4A , D74A), as well as tumor-promoting somatic fusion genes and epigenetic deregulation. The study also found that a derived MNTI cell line was sensitive to inhibitors of lysine demethylase.[26]

Although MNTI is an aggressive benign tumor, malignant variants have been reported. Of reported cases, mostly of the brain and skull, 6.5% have exhibited malignant behavior.[18] Nevertheless, some authors believe the estimation of 6.5% is probably exaggerated in the literature because unusual malignant cases are more likely to be reported.[1, 22] Metastatic spread of MNTI occurs infrequently, in less than 5% of malignant cases. Management of these rare cases is different. Few, if any, parameters exist, either clinically or histologically, to predict the development of metastatic lesions.[34] In a few cases reported as malignant, the histologic features have taken on a neuroblastomalike appearance.[9, 37]

Long-Term Monitoring

Address the documented 20% recurrence rate of melanotic neuroectodermal tumor of infancy (MNTI) in the postoperative care by monitoring the patient with physical and radiographic examination at monthly intervals for the first two postoperative years. Moreover, an estimated malignant transformation rate of 6.5% highlights the possibly serious nature of this tumor and the need for careful clinical evaluation and close follow-up of affected patients, especially for tumors located in the brain and skull.

Permanent reconstruction of the maxillary alveolus and missing dentition may have to be delayed until after growth is completed, often in the teenage years. In the interim, transitional removable partial dentures may be necessary. The skills of an orthodontist, prosthodontist, oral surgeon, and/or dentist may be required, based on the extent of the missing structures, to correct any functional and cosmetic deformity.

Author

Leticia Ferreira, DDS, MS, Assistant Professor of Pathology and Medicine, Department of Dental Practice, University of the Pacific, Arthur A Dugoni School of Dentistry

Disclosure: Nothing to disclose.

Specialty Editors

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Drore Eisen, MD, DDS, Consulting Staff, Dermatology of Southwest Ohio

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Additional Contributors

Mark G Lebwohl, MD, Chairman, Department of Dermatology, Mount Sinai School of Medicine

Disclosure: Received none from Amgen for consultant & investigator; Received none from Novartis for consultant & investigator; Received none from Pfizer for consultant & investigator; Received none from Celgene Corporation for consultant & investigator; Received none from Clinuvel for consultant & investigator; Received none from Eli Lilly & Co. for consultant & investigator; Received none from Janssen Ortho Biotech for consultant & investigator; Received none from LEO Pharmaceuticals for consultant & inves.

Acknowledgements

James Burns, DDS, PhD, MEd Chairman, Professor, Department of Oral and Maxillofacial Pathology, Assistant Dean, Clinical Education, Virginia Commonwealth University School of Dentistry

James Burns is a member of the following medical societies: American Academy of Oral and Maxillofacial Pathology, American Association for Cancer Education, American Dental Association, and International Association of Oral Pathologists

Disclosure: Nothing to disclose.

William M Carpenter, DDS, MS Professor, Chairman, Department of Pathology and Medicine, University of the Pacific, Arthur A Dugoni School of Dentistry

William M Carpenter, DDS, MS is a member of the following medical societies: American Academy of Oral and Maxillofacial Pathology and American Academy of Oral Medicine

Disclosure: Nothing to disclose.

Robert Strauss, DDS Associate Professor, Department of Oral and Maxillofacial Surgery, Virginia Commonwealth University School of Dentistry

Robert Strauss is a member of the following medical societies: American Association of Oral and Maxillofacial Surgeons and American Dental Association

Disclosure: Nothing to disclose.

References

  1. Chi A, Neville B, Damm D, Allen C. Melanotic Neuroectodermal Tumor of Infancy. Oral & Maxillofacial Pathology. 4th ed. St Louis, Mo: Saunders/Elsevier; 2016. 500-1.
  2. Krompecher Z. Zur histogenese and morphologic den adamantinome und sonstiger kiefergeschwulste. Beitr Pathol Anat. 1918. 165-97.
  3. Allen MS Jr, Harrison W, Jahrsdoerfer RA. "Retinal anlage" tumors. Melanotic progonoma, melanotic adamantinoma, pigmented epulis, melanotic neuroectodermal tumor of infancy, benign melanotic tumor of infancy. Am J Clin Pathol. 1969 Mar. 51(3):309-14. [View Abstract]
  4. Kilmer JB. The pigmented ameloblastomas or "retinal anlage" tumors. Report of two cases. Laryngoscope. 1963 Oct. 73:1303-8. [View Abstract]
  5. Lurie HI. Congential melanocarcinoma, melanotic adamantinoma, retinal anlage tumor, progonoma, and pigmented epulis of infancy. Summary and review of the literature and report of the first case in an adult. Cancer. 1961 Sep-Oct. 14:1090-108. [View Abstract]
  6. Borello ED, Gorlin RJ. Melanotic neuroectodermal tumor of infancy--a neoplasm of neural crese origin. Report of a case associated with high urinary excretion of vanilmandelic acid. Cancer. 1966 Feb. 19(2):196-206. [View Abstract]
  7. Cutler LS, Chaudhry AP, Topazian R. Melanotic neuroectodermal tumor of infancy: an ultrastructural study, literature review, and reevaluation. Cancer. 1981 Jul 15. 48(2):257-70. [View Abstract]
  8. Pettinato G, Manivel JC, d'Amore ES, Jaszcz W, Gorlin RJ. Melanotic neuroectodermal tumor of infancy. A reexamination of a histogenetic problem based on immunohistochemical, flow cytometric, and ultrastructural study of 10 cases. Am J Surg Pathol. 1991 Mar. 15(3):233-45. [View Abstract]
  9. Dehner LP, Sibley RK, Sauk JJ Jr, Vickers RA, Nesbit ME, Leonard AS, et al. Malignant melanotic neuroectodermal tumor of infancy: a clinical, pathologic, ultrastructural and tissue culture study. Cancer. 1979 Apr. 43(4):1389-410. [View Abstract]
  10. Navas Palacios JJ. Malignant melanotic neuroectodermal tumor: light and electron microscopic study. Cancer. 1980 Aug 1. 46(3):529-36. [View Abstract]
  11. Chaudhary A, Wakhlu A, Mittal N, Misra S, Mehrotra D, Wakhlu AK. Melanotic neuroectodermal tumor of infancy: 2 decades of clinical experience with 18 patients. J Oral Maxillofac Surg. 2009 Jan. 67(1):47-51. [View Abstract]
  12. Miękus N, Olędzka I, Plenis A, Kowalski P, Bień E, Miękus A, et al. Determination of urinary biogenic amines' biomarker profile in neuroblastoma and pheochromocytoma patients by MEKC method with preceding dispersive liquid-liquid microextraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Nov 15. 1036-1037:114-123. [View Abstract]
  13. Rachidi S, Sood AJ, Patel KG, Nguyen SA, Hamilton H, Neville BW, et al. Melanotic Neuroectodermal Tumor of Infancy: A Systematic Review. J Oral Maxillofac Surg. 2015 Oct. 73 (10):1946-56. [View Abstract]
  14. Agarwal P, Saxena S, Kumar S, Gupta R. Melanotic neuroectodermal tumor of infancy: Presentation of a case affecting the maxilla. J Oral Maxillofac Pathol. 2010 Jan. 14(1):29-32. [View Abstract]
  15. Gorhan C, Soto-Ares G, Ruchoux MM, Blond S, Pruvo JP. Melanotic neuroectodermal tumour of the pineal region. Neuroradiology. 2001 Nov. 43(11):944-7. [View Abstract]
  16. Vajtai I, Suták I, Varga Z. Melanotic progonoma as a component of ovarian teratoma. Histopathology. 2000 Mar. 36(3):283-5. [View Abstract]
  17. Schulz DM. A malignant, melanotic neoplasm of the uterus, resembling the retinal anlage tumors; report of a case. Am J Clin Pathol. 1957 Nov. 28(5):524-32. [View Abstract]
  18. Kruse-Lösler B, Gaertner C, Bürger H, Seper L, Joos U, Kleinheinz J. Melanotic neuroectodermal tumor of infancy: systematic review of the literature and presentation of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Aug. 102(2):204-16. [View Abstract]
  19. Neven J, Hulsbergen-van der Kaa C, Groot-Loonen J, de Wilde PC, Merkx MA. Recurrent melanotic neuroectodermal tumor of infancy: a proposal for treatment protocol with surgery and adjuvant chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Oct. 106(4):493-6. [View Abstract]
  20. Davis JM, DeBenedictis M, Frank DK, Lessin ME. Melanotic neuroectodermal tumor of infancy: a wolf in sheep's clothing. Ann Otol Rhinol Laryngol. 2015 Feb. 124 (2):97-101. [View Abstract]
  21. Fakuade BO, Adeoye JB. Melanotic neuroectodermal tumor of infancy: a rare presentation of an extremely rare neoplasm and diagnostic implications in Gombe, Nigeria. Pan Afr Med J. 2017. 28:5. [View Abstract]
  22. Madrid C, Aziza J, Hlali A, Bouferrache K, Abarca M. Melanotic neuroectodermal tumour of infancy: a case report and review of the aetiopathogenic hypotheses. Med Oral Patol Oral Cir Bucal. 2010 Sep 1. 15(5):e739-42. [View Abstract]
  23. Lacy SR, Kuhar M. Melanotic neuroectodermal tumor of infancy presenting in the subcutaneous soft tissue of the thigh. Am J Dermatopathol. 2010 May. 32(3):282-6. [View Abstract]
  24. Choi IS, Kook H, Han DK, Baek HJ, Jung ST, Lee JH, et al. Melanotic neuroectodermal tumor of infancy in the femur: a case report and review of the literature. J Pediatr Hematol Oncol. 2007 Dec. 29(12):854-7. [View Abstract]
  25. Ma Y, Zheng J, Yang S, Zhu H, Dong K, Xiao X, et al. Melanotic neuroectodermal tumor of infancy in the soft tissue of the forearm: report of a case. Int J Clin Exp Pathol. 2015. 8 (10):13584-9. [View Abstract]
  26. Barnes DJ, Hookway E, Athanasou N, Kashima T, Oppermann U, Hughes S, et al. A germline mutation of CDKN2A and a novel RPLP1-C19MC fusion detected in a rare melanotic neuroectodermal tumor of infancy: a case report. BMC Cancer. 2016 Aug 12. 16:629. [View Abstract]
  27. Steinberg B, Shuler C, Wilson S. Melanotic neuroectodermal tumor of infancy: evidence for multicentricity. Oral Surg Oral Med Oral Pathol. 1988 Dec. 66(6):666-9. [View Abstract]
  28. Pontius EE, Dziabis MD, Foster JA. Multicentric melano-ameloblastoma of the maxilla. Cancer. 1965 Mar. 18:381-7. [View Abstract]
  29. Haque S, McCarville MB, Sebire N, McHugh K. Melanotic neuroectodermal tumour of infancy: CT and MR findings. Pediatr Radiol. 2012 Jun. 42(6):699-705. [View Abstract]
  30. Fowler DJ, Chisholm J, Roebuck D, Newman L, Malone M, Sebire NJ. Melanotic neuroectodermal tumor of infancy: clinical, radiological, and pathological features. Fetal Pediatr Pathol. 2006 Mar-Apr. 25(2):59-72. [View Abstract]
  31. Atkinson GO Jr, Davis PC, Patrick LE, Winn KJ, Ball TI, Wyly JB. Melanotic neuroectodermal tumor of infancy. MR findings and a review of the literature. Pediatr Radiol. 1989. 20(1-2):20-2. [View Abstract]
  32. Koob M, Fayard C, Pariente D, Adamsbaum C, Franchi-Abella S. Prenatal Diagnosis Of Orbital Melanotic Neuroectodermal Tumor Of Infancy. Ultrasound Obstet Gynecol. 2015 Jan 16. [View Abstract]
  33. Koral K, Derinkuyu B, Timmons C, Schwartz-Dabney CL, Swift D. Melanotic neuroectodermal tumor of infancy: report of one calvarial lesion with T1 shortening and one maxillary lesion. Clin Imaging. 2010 Sep-Oct. 34(5):382-4. [View Abstract]
  34. Kapadia SB, Frisman DM, Hitchcock CL, Ellis GL, Popek EJ. Melanotic neuroectodermal tumor of infancy. Clinicopathological, immunohistochemical, and flow cytometric study. Am J Surg Pathol. 1993 Jun. 17(6):566-73. [View Abstract]
  35. Woo SB. Melanotic neuroectodermal tumor of infancy. In: Oral Pathology: A Comprehensive Atlas and Text. 1st ed. Philadelphia, Pa: Saunders/Elsevier; 2012. 207-09.
  36. Dammann O, Hagel C, Allers B, et al. Malignant melanotic neuroectodermal tumor of infancy. Childs Nerv Syst. 1995 Mar. 11(3):186-8. [View Abstract]
  37. Block JC, Waite DE, Dehner LP, Leonard AS, Ogle RG, Gatto DJ. Pigmented neuroectodermal tumor of infancy. An example of rarely expressed malignant behavior. Oral Surg Oral Med Oral Pathol. 1980 Apr. 49(4):279-85. [View Abstract]
  38. Nicosia G, Spennato P, Aliberti F, Cascone D, Quaglietta L, Errico ME, et al. Giant melanotic neuroectodermal tumor of infancy (melanotic progonoma) of the head and neck: report of a malignant case. J Neurosurg Pediatr. 2017 Feb 24. 1-8. [View Abstract]
  39. Barrett AW, Morgan M, Ramsay AD, Farthing PM, Newman L, Speight PM. A clinicopathologic and immunohistochemical analysis of melanotic neuroectodermal tumor of infancy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Jun. 93(6):688-98. [View Abstract]
  40. Nelson ZL, Newman L, Loukota RA, Williams DM. Melanotic neuroectodermal tumour of infancy: an immunohistochemical and ultrastructural study. Br J Oral Maxillofac Surg. 1995 Dec. 33(6):375-80. [View Abstract]
  41. de Souza PE, Merly F, Maia DM, Castro WH, Gomez RS. Cell cycle-associated proteins in melanotic neuroectodermal tumor of infancy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Oct. 88(4):466-8. [View Abstract]
  42. Nitta T, Endo T, Tsunoda A, Kadota Y, Matsumoto T, Sato K. Melanotic neuroectodermal tumor of infancy: a molecular approach to diagnosis. Case report. J Neurosurg. 1995 Jul. 83(1):145-8. [View Abstract]
  43. Khoddami M, Squire J, Zielenska M, Thorner P. Melanotic neuroectodermal tumor of infancy: a molecular genetic study. Pediatr Dev Pathol. 1998 Jul-Aug. 1(4):295-9. [View Abstract]
  44. Moreau A, Galmiche L, Minard-Colin V, Rachwalski M, Belhous K, Orbach D, et al. Melanotic neuroectodermal tumor of infancy (MNTI) of the head and neck: A French multicenter study. J Craniomaxillofac Surg. 2018 Feb. 46 (2):201-206. [View Abstract]
  45. Dashti SR, Cohen ML, Cohen AR. Role of radical surgery for intracranial melanotic neuroectodermal tumor of infancy: case report. Neurosurgery. 1999 Jul. 45(1):175-8. [View Abstract]
  46. Béogo R, Nikiéma Z, Traoré SS, Bouletreau P. Maxillary melanotic neuroectodermal tumor of infancy management: is conservative surgery the best approach?. J Craniofac Surg. 2013 Jul. 24(4):e338-40. [View Abstract]
  47. Rustagi A, Roychoudhury A, Karak AK. Melanotic neuroectodermal tumor of infancy of the maxilla: a case report with review of literature. J Oral Maxillofac Surg. 2011 Apr. 69(4):1120-4. [View Abstract]
  48. Franchi G, Sleilati F, Soupre V, Boudjemaa S, Josset P, Diner PA, et al. Melanotic neuroectodermal tumour of infancy involving the orbit and maxilla: surgical management and follow-up strategy. Br J Plast Surg. 2002 Sep. 55(6):526-9. [View Abstract]
  49. Pierre-Kahn A, Cinalli G, Lellouch-Tubiana A, Villarejo FJ, Sainte-Rose C, Pfister A, et al. Melanotic neuroectodermal tumor of the skull and meninges in infancy. Pediatr Neurosurg. 1992. 18(1):6-15. [View Abstract]
  50. Hoshina Y, Hamamoto Y, Suzuki I, Nakajima T, Ida-Yonemochi H, Saku T. Melanotic neuroectodermal tumor of infancy in the mandible: report of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 May. 89(5):594-9. [View Abstract]
  51. Mirich DR, Blaser SI, Harwood-Nash DC, Armstrong DC, Becker LE, Posnick JC. Melanotic neuroectodermal tumor of infancy: clinical, radiologic, and pathologic findings in five cases. AJNR Am J Neuroradiol. 1991 Jul-Aug. 12(4):689-97. [View Abstract]
  52. Klimek L, Klein HM, Schneider W, Mösges R, Schmelzer B, Voy ED. Stereolithographic modelling for reconstructive head surgery. Acta Otorhinolaryngol Belg. 1993. 47(3):329-34. [View Abstract]
  53. Woessmann W, Neugebauer M, Gossen R, et al. Successful chemotherapy for melanotic neuroectodermal tumor of infancy in a baby. Med Pediatr Oncol. 2003 Mar. 40(3):198-9. [View Abstract]
  54. Gomes CC, Diniz MG, de Menezes GH, Castro WH, Gomez RS. BRAFV600E Mutation in Melanotic Neuroectodermal Tumor of Infancy: Toward Personalized Medicine?. Pediatrics. 2015 Jul. 136 (1):e267-9. [View Abstract]

Melanotic neuroectodermal tumor of infancy presents as a rapidly growing bluish mass on the anterior aspect of the maxilla.

Axial CT, bone window, noncontrasted scan demonstrates expansile lytic lesion of the left maxilla producing displacement of dental follicles.

The biphasic population of cells demonstrates alveolar structures lined by cuboidal epithelioid cells demonstrating granules of dark-brown melanin pigment. The second cell type is neuroblastic in appearance and consists of small, round, hyperchromatic cells.

Melanotic neuroectodermal tumor of infancy presents as a rapidly growing bluish mass on the anterior aspect of the maxilla.

Axial CT, bone window, noncontrasted scan demonstrates expansile lytic lesion of the left maxilla producing displacement of dental follicles.

The biphasic population of cells demonstrates alveolar structures lined by cuboidal epithelioid cells demonstrating granules of dark-brown melanin pigment. The second cell type is neuroblastic in appearance and consists of small, round, hyperchromatic cells.